Novel Approach for Bone Marrow Transplantation Conditioning in Acute Myelogenous Leukemia not Responding to the Induction Therapy Using Etoposide Carried in Lipid Core Nanoparticles: A Pilot Clinical Study

Use of paclitaxel carried in lipid core nanoparticles in patients with late-stage solid cancers with bone metastases: Lack of toxicity and therapeutic benefits

“…LDE-PTX was recently tested patients with ovarian cancer as third-fourth line chemotherapy [30] and the tolerability and safety was shown at the standard 175 mg/m 2 body surface PTX dose level [38] , [39] , [40] . Furthermore, the capacity of LDE to buffer drug toxicity in cancer patients had been also shown with the formulations of LDE with carmustine [21] and etoposide [20] , [31] . The use of LDE-PTX, in addition to provide chemotherapy without the toxicity burden to the patients, has potential of greater cost effectiveness by avoiding the use of medications to treat drug side effects and of patient hospitalizations.…”

“…In experiments with animals with implanted tumors, drugs such as paclitaxel (PTX) [25] , [26] , carmustine [27] , daunorubicin [28] and etoposide [29] incorporated to LDE increased the anti-tumor action, whereas the drug toxicity was markedly decreased. The inherent ability of LDE to drastically reduce the toxicity of chemotherapeutic agents was also shown in clinical trials enrolling patients with advanced cancers [19] , [20] , [21] , [22] , [24] , [30] , [31] , [32] .…”